Improving prevention and treatment for opioid use disorder and HIV in prisons
NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings
This study is looking at how to better provide long-lasting medications for people dealing with opioid use disorder and those at risk for HIV while they are in jail, so they can get the help they need both during their time in custody and when they return to the community.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10907969 on NIH RePORTER |
What this research studies
This research focuses on enhancing the delivery of long-acting medications for opioid use disorder and pre-exposure prophylaxis (PrEP) to individuals in carceral settings. It aims to address the high rates of opioid use disorder and HIV among incarcerated populations by developing a co-packaged intervention that combines these treatments. The study will explore how to effectively implement these interventions during incarceration and upon re-entry into the community, ensuring that patients receive the support they need for better health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who are currently incarcerated and have either opioid use disorder or are at risk for HIV.
Not a fit: Patients who are not incarcerated or do not have opioid use disorder or HIV risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the rates of opioid use disorder and HIV among incarcerated individuals, leading to improved health and social outcomes.
How similar studies have performed: Previous research has shown that integrated approaches to treating opioid use disorder and preventing HIV can lead to improved health outcomes, indicating that this approach has potential for success.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Brinkley-Rubinstein, Lauren — Duke University
- Study coordinator: Brinkley-Rubinstein, Lauren
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.